Immune Netw.  2019 Oct;19(5):e36. 10.4110/in.2019.19.e36.

Mesenchymal Stem Cells Ameliorate Renal Inflammation in Adriamycin-induced Nephropathy

  • 1College of Pharmacy, Chungbuk National University, Cheongju 28160, Korea.
  • 2Bioengineering Institute, Corestem Inc., Seoul 04763, Korea.
  • 3Hanyang University Hospital for Rheumatic Diseases, Seoul 04763, Korea.
  • 4College of Pharmacy, Korea University, Sejong 30019, Korea.


Mesenchymal stem cells (MSCs) ameliorate the renal injury in Adriamycin (ADR)-induced nephropathy, but the mechanisms underlying their efficacy remain incompletely understood. In this study, we demonstrated that MSCs increased the survival, recovered body weight loss, and decreased proteinuria and serum creatinine levels in ADR-treated mice. MSCs also prevented podocyte damage and renal fibrosis by decreasing the expression of fibronectin, collagen 1α1, and α-smooth muscle actin. From a mechanistic perspective, MSCs inhibited renal inflammation by lowering the expression of CCL4, CCL7, CCL19, IFN-α/β, TGF-β, TNF-α, and chitinase 3-like 1. In summary, our data demonstrate that MSCs improve renal functions by inhibiting renal inflammation in ADR-induced nephropathy.


Mesenchymal stem cells; Inflammation; Podocytes; Fibrosis
Full Text Links
  • IN
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: